‘Why asthma still kills, the National Review of Asthma Deaths’ (NRAD) was the first national investigation of asthma deaths in the UK and the largest study worldwide and was conducted in 2014. The primary aim was to understand the circumstances surrounding asthma deaths in order to identify avoidable factors and make recommendations to improve care and reduce the number of deaths.
Dr Mark Levy was the National NRAD Clinical Lead and one of the lead authors of the NRAD document. We are delighted to welcome Mark to discuss how far we have progressed since the publication of NRAD in 2014 and particularly how he feels pharmacists working in primary care and community pharmacy can contribute to the reduction in preventable asthma deaths.
During this webinar you will learn about:
- A case study explaining why asthma remains a dangerous disease.
- The headline findings of NRAD.
- How much progress has been made since NRAD was published?
- Case studies involving excellent interprofessional work between community pharmacy and general practice to improve the care of people with asthma.
- The importance of the overuse of short-acting beta-agonists and when to intervene.
- The importance of the post asthma attack review and on-going care.
- Q&A chaired by Johnathan Laird.
Dr Levy graduated as a medical doctor in Pretoria, South Africa, in 1974. Since 1977 he has been practising as a general practitioner in London with a special interest in respiratory diseases. His experience, in addition to caring for patients in a busy general practice, includes research, authoring papers and books, editing a medical journal, research and lecturing about respiratory disease. For 13 years, he trained young doctors wishing to become general practitioners.
Dr Levy is currently a locum GP in London. He was one of the six founders of the GPIAG – now known as the PCRS, Clinical Lead for NRAD (2011-2014) and is a member of the GINA Board of Directors and Dissemination and Implementation Committee. His full CV is available here.
The webinar has been supported by members of the pharmaceutical industry. These companies have had no input into any aspect of the webinar.